• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在白细胞介素-12诱导的、由γ-干扰素介导的实验性自身免疫性脑脊髓炎抑制过程中,程序性死亡受体1/程序性死亡配体途径被上调。

The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gamma.

作者信息

Cheng Xiaodong, Zhao Zhao, Ventura Elvira, Gran Bruno, Shindler Kenneth S, Rostami Abdolmohamad

机构信息

Department of Neurology, Jefferson Hospital for Neuroscience, Thomas Jefferson University, 900 Walnut Street, Philadelphia, PA 19107, USA.

出版信息

J Neuroimmunol. 2007 Apr;185(1-2):75-86. doi: 10.1016/j.jneuroim.2007.01.012. Epub 2007 Feb 23.

DOI:10.1016/j.jneuroim.2007.01.012
PMID:17320975
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2716290/
Abstract

Experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), is mediated by autoantigen-specific T-helper1 (Th1) cells. IL-12, an inducer of Th1 cell development, exerts immunomodulatory effects in EAE. Programmed death-1 (PD-1) and PD-1 ligand (PD-L), new members of the B7 superfamily of costimulatory molecules, play a critical role in regulating EAE. Whether the interaction of IL-12 and the PD-1/PD-L pathway regulates EAE is unclear. We have previously shown that IL-12 suppresses EAE induced by MOG35-55 in C57BL/6 mice, but not in IFN-gamma-deficient mice, suggesting that IFN-gamma is required for the inhibitory effects of IL-12 on EAE. In the current study, PD-L1 expression is up-regulated following IL-12 treatment in wild-type mice, but not in IFN-(-deficient EAE mice. Similarly, IL-12 induces IFN-gamma and PD-L1 expression in cultured MOG-specific T cells from wild-type mice but not from IFN-gamma-deficient mice. Furthermore, PD-L1 expression increased specifically in CD11b+ antigen presenting cells (APCs) after IL-12 administration. These data suggest that one mechanism of IL-12 suppression of EAE is mediated by PD-1/PD-L signaling downstream of IFN-gamma induction in CD11b+ APCs. The regulation of PD-1/PD-L1 may have potential therapeutic effects for EAE and MS.

摘要

实验性自身免疫性脑脊髓炎(EAE)是多发性硬化症(MS)的一种动物模型,由自身抗原特异性辅助性T细胞1(Th1)介导。白细胞介素12(IL-12)是Th1细胞发育的诱导剂,在EAE中发挥免疫调节作用。程序性死亡1(PD-1)和PD-1配体(PD-L)是共刺激分子B7超家族的新成员,在调节EAE中起关键作用。IL-12与PD-1/PD-L途径的相互作用是否调节EAE尚不清楚。我们之前已经表明,IL-12可抑制C57BL/6小鼠中由MOG35-55诱导的EAE,但在干扰素-γ缺陷小鼠中则不能,这表明干扰素-γ是IL-12对EAE产生抑制作用所必需的。在当前研究中,野生型小鼠经IL-12处理后PD-L1表达上调,但在干扰素-γ缺陷的EAE小鼠中则不然。同样,IL-12可诱导野生型小鼠培养的MOG特异性T细胞中干扰素-γ和PD-L1表达,但不能诱导干扰素-γ缺陷小鼠的此类细胞表达。此外,给予IL-12后,PD-L1表达在CD11b+抗原呈递细胞(APC)中特异性增加。这些数据表明,IL-12抑制EAE的一种机制是由CD11b+ APC中干扰素-γ诱导下游的PD-1/PD-L信号介导的。PD-1/PD-L1的调节可能对EAE和MS具有潜在治疗作用。

相似文献

1
The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gamma.在白细胞介素-12诱导的、由γ-干扰素介导的实验性自身免疫性脑脊髓炎抑制过程中,程序性死亡受体1/程序性死亡配体途径被上调。
J Neuroimmunol. 2007 Apr;185(1-2):75-86. doi: 10.1016/j.jneuroim.2007.01.012. Epub 2007 Feb 23.
2
PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE.中枢神经系统中髓系来源的抗原呈递细胞(APC)上表达的程序性死亡受体1(PD-1)配体调节实验性自身免疫性脑脊髓炎(EAE)中的T细胞反应。
Eur J Immunol. 2008 Oct;38(10):2706-17. doi: 10.1002/eji.200838137.
3
Novel immunomodulatory properties of berbamine through selective down-regulation of STAT4 and action of IFN-gamma in experimental autoimmune encephalomyelitis.小檗胺在实验性自身免疫性脑脊髓炎中通过选择性下调信号转导和转录激活因子4(STAT4)及γ干扰素(IFN-γ)的作用发挥新型免疫调节特性。
J Immunol. 2008 Jul 15;181(2):1491-8. doi: 10.4049/jimmunol.181.2.1491.
4
Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis.程序性死亡配体1[校正后]和程序性死亡配体2[校正后]在调节实验性自身免疫性脑脊髓炎易感性和慢性进展中的差异作用
J Immunol. 2006 Mar 15;176(6):3480-9. doi: 10.4049/jimmunol.176.6.3480.
5
Therapeutic role of interferon-γ in experimental autoimmune encephalomyelitis is mediated through a tolerogenic subset of splenic CD11b myeloid cells.γ 干扰素在实验性自身免疫性脑脊髓炎中的治疗作用是通过脾 CD11b 髓样细胞的耐受亚群介导的。
J Neuroinflammation. 2024 May 31;21(1):144. doi: 10.1186/s12974-024-03126-3.
6
Role of IL-12 receptor beta 1 in regulation of T cell response by APC in experimental autoimmune encephalomyelitis.白细胞介素-12受体β1在实验性自身免疫性脑脊髓炎中抗原呈递细胞对T细胞反应调节中的作用
J Immunol. 2003 Nov 1;171(9):4485-92. doi: 10.4049/jimmunol.171.9.4485.
7
Mice deficient for CCR6 fail to control chronic experimental autoimmune encephalomyelitis.缺乏CCR6的小鼠无法控制慢性实验性自身免疫性脑脊髓炎。
J Neuroimmunol. 2009 Aug 18;213(1-2):91-9. doi: 10.1016/j.jneuroim.2009.05.011. Epub 2009 Jun 17.
8
Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis.对B7缺陷小鼠的研究揭示了B7共刺激在实验性自身免疫性脑脊髓炎的诱导期和效应期均起关键作用。
J Exp Med. 1999 Sep 6;190(5):733-40. doi: 10.1084/jem.190.5.733.
9
PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis.程序性死亡受体1(PD-1)/程序性死亡配体1(PD-L1)的相互作用而非程序性死亡受体1(PD-1)/程序性死亡配体2(PD-L2)的相互作用,调控实验性自身免疫性脑脊髓炎的严重程度。
J Neuroimmunol. 2007 Jan;182(1-2):124-34. doi: 10.1016/j.jneuroim.2006.10.006. Epub 2006 Dec 19.
10
Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells.垂体腺苷酸环化酶激活多肽(PACAP)通过抑制抗原呈递细胞的功能来改善实验性自身免疫性脑脊髓炎。
Mult Scler. 2004 Dec;10(6):651-9. doi: 10.1191/1352458504ms1096oa.

引用本文的文献

1
Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer.预测高危非肌层浸润性膀胱癌对卡介苗的反应
Transl Cancer Res. 2024 Nov 30;13(11):6489-6502. doi: 10.21037/tcr-24-180. Epub 2024 Jul 30.
2
Therapeutic role of interferon-γ in experimental autoimmune encephalomyelitis is mediated through a tolerogenic subset of splenic CD11b myeloid cells.γ 干扰素在实验性自身免疫性脑脊髓炎中的治疗作用是通过脾 CD11b 髓样细胞的耐受亚群介导的。
J Neuroinflammation. 2024 May 31;21(1):144. doi: 10.1186/s12974-024-03126-3.
3
Unlocking the 'ova'-coming power: immunotherapy's role in shaping the future of ovarian cancer treatment.

本文引用的文献

1
Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system.白细胞介素27在中枢神经系统慢性炎症期间对产生白细胞介素17的辅助性T细胞的发育起负向调节作用。
Nat Immunol. 2006 Sep;7(9):937-45. doi: 10.1038/ni1376. Epub 2006 Aug 13.
2
Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis.程序性死亡配体1[校正后]和程序性死亡配体2[校正后]在调节实验性自身免疫性脑脊髓炎易感性和慢性进展中的差异作用
J Immunol. 2006 Mar 15;176(6):3480-9. doi: 10.4049/jimmunol.176.6.3480.
3
解锁“卵母细胞”潜能:免疫疗法在塑造卵巢癌治疗未来中的作用。
Med Oncol. 2024 Jan 29;41(3):67. doi: 10.1007/s12032-023-02281-6.
4
Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy.奥帕甘尼布(ABC294640)诱导免疫原性肿瘤细胞死亡并增强检查点抗体治疗。
Int J Mol Sci. 2023 Nov 29;24(23):16901. doi: 10.3390/ijms242316901.
5
Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice.免疫检查点为基础的免疫疗法在多发性硬化中的进展:原理与实践。
Cell Commun Signal. 2023 Nov 9;21(1):321. doi: 10.1186/s12964-023-01289-9.
6
Role of regulation of PD-1 and PD-L1 expression in sepsis.PD-1 和 PD-L1 表达调控在脓毒症中的作用。
Front Immunol. 2023 Mar 9;14:1029438. doi: 10.3389/fimmu.2023.1029438. eCollection 2023.
7
Role of the PD-1/PD-L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions.PD-1/PD-L1 信号在多发性硬化症和实验性自身免疫性脑脊髓炎中的作用:最新见解与未来方向。
Mol Neurobiol. 2021 Dec;58(12):6249-6271. doi: 10.1007/s12035-021-02495-7. Epub 2021 Sep 3.
8
Emerging Role of PD-1 in the Central Nervous System and Brain Diseases.PD-1 在中枢神经系统和脑部疾病中的新作用。
Neurosci Bull. 2021 Aug;37(8):1188-1202. doi: 10.1007/s12264-021-00683-y. Epub 2021 Apr 20.
9
Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies.靶向癌症免疫检查点抑制剂治疗中的核酸介导免疫。
Signal Transduct Target Ther. 2020 Nov 20;5(1):270. doi: 10.1038/s41392-020-00347-9.
10
PD-1 Blockade Reverses Obesity-Mediated T Cell Priming Impairment.PD-1 阻断逆转肥胖介导的 T 细胞启动损伤。
Front Immunol. 2020 Oct 29;11:590568. doi: 10.3389/fimmu.2020.590568. eCollection 2020.
IL-27 subunits and its receptor (WSX-1) mRNAs are markedly up-regulated in inflammatory cells in the CNS during experimental autoimmune encephalomyelitis.
在实验性自身免疫性脑脊髓炎期间,白细胞介素-27亚基及其受体(WSX-1)的信使核糖核酸在中枢神经系统的炎性细胞中显著上调。
J Neurol Sci. 2005 May 15;232(1-2):3-9. doi: 10.1016/j.jns.2004.12.013.
4
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.白细胞介素-23驱动致病性T细胞群体,引发自身免疫性炎症。
J Exp Med. 2005 Jan 17;201(2):233-40. doi: 10.1084/jem.20041257.
5
PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells.PD-1配体,即未成熟、记忆及近期活化的人类CD4+ T细胞活化的负性调节因子。
Cell Immunol. 2004 Aug;230(2):89-98. doi: 10.1016/j.cellimm.2004.09.004.
6
Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination.IL-12/IL-23系统在中枢神经系统炎性脱髓鞘中T细胞反应调节中的作用
Crit Rev Immunol. 2004;24(2):111-28. doi: 10.1615/critrevimmunol.v24.i2.20.
7
IL-12 and IL-23: master regulators of innate and adaptive immunity.白细胞介素-12和白细胞介素-23:固有免疫和适应性免疫的主要调节因子。
Immunol Rev. 2004 Dec;202:96-105. doi: 10.1111/j.0105-2896.2004.00214.x.
8
Antigen targeting to CD11b allows efficient presentation of CD4+ and CD8+ T cell epitopes and in vivo Th1-polarized T cell priming.抗原靶向CD11b可实现CD4+和CD8+ T细胞表位的高效呈递以及体内Th1极化的T细胞启动。
J Immunol. 2004 Nov 15;173(10):6089-97. doi: 10.4049/jimmunol.173.10.6089.
9
Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases).严重医源性淋巴细胞减少症(为治疗自身免疫性疾病而诱发)的恢复情况及后果。
Clin Immunol. 2004 Dec;113(3):285-98. doi: 10.1016/j.clim.2004.07.006.
10
Early administration of IL-12 suppresses EAE through induction of interferon-gamma.早期给予白细胞介素-12通过诱导γ干扰素抑制实验性自身免疫性脑脊髓炎。
J Neuroimmunol. 2004 Nov;156(1-2):123-31. doi: 10.1016/j.jneuroim.2004.07.019.